S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

UCB Stock Forecast, Price & News

0.00 (0.00%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
300 shs
Market Capitalization
$20.78 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive UCBJF News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCB logo

About UCB

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$6.11 billion
Cash Flow
$5.95 per share
Book Value
$42.71 per share


Pretax Margin




Free Float
Market Cap
$20.78 billion
Not Optionable

Company Calendar

Fiscal Year End

Social Links


Overall MarketRank

1.14 out of 5 stars

Analyst Opinion: 1.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

UCB (OTCMKTS:UCBJF) Frequently Asked Questions

Is UCB a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UCB stock.
View analyst ratings for UCB
or view top-rated stocks.

How has UCB's stock been impacted by Coronavirus (COVID-19)?

UCB's stock was trading at $97.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, UCBJF stock has increased by 13.1% and is now trading at $109.96.
View which stocks have been most impacted by COVID-19

Are investors shorting UCB?

UCB saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 768,200 shares, an increase of 51.4% from the December 15th total of 507,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 7,682.0 days.
View UCB's Short Interest

What price target have analysts set for UCBJF?

9 Wall Street analysts have issued 12 month price targets for UCB's stock. Their forecasts range from $91.00 to $150.00. On average, they expect UCB's stock price to reach $116.77 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price.
View analysts' price targets for UCB
or view top-rated stocks among Wall Street analysts.

Who are UCB's key executives?

UCB's management team includes the following people:
  • Jean-Christophe Tellier, Chief Executive Officer & Executive Director
  • Sandrine Dufour, Chief Financial Officer & Executive Vice President
  • Iris Löw-Friedrich, Chief Medical Officer & EVP-Development
  • Dhavalkumar Patel, Chief Scientific Officer & Executive VP
  • Herman de Prins, Chief Information Officer

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

How do I buy shares of UCB?

Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $109.96.

How much money does UCB make?

UCB has a market capitalization of $20.78 billion and generates $6.11 billion in revenue each year.

How many employees does UCB have?

UCB employs 8,371 workers across the globe.

When was UCB founded?

UCB was founded in 1928.

What is UCB's official website?

The official website for UCB is www.ucb.com.

Where are UCB's headquarters?

How can I contact UCB?

UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company can be reached via phone at (322) 559-9999, via email at [email protected], or via fax at 32-2559-9900.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.